

GROW¹ GLOBAL

LONDON

Grow London Global is a free 12-month programme for fast-growth and credible London-based companies that want to expand internationally.

For more information, visit: grow.london/global

The programme which covers Life Sciences, Sustainability, Creative, FinTech & Enterprise technologies, has helped 1,400 London scaleups including world renowned companies Elvie, Revolut and Brompton Bicycles.

Grow London Global offers each company expert advice, workshops, events, as well as unrivalled opportunities networking opportunities to make valuable contacts with corporates, non-profits, academia and investors in the UK and target markets across the world.

LIFE SCIENCE COMPANIES AT BIOJAPAN



Curenetics uses AI to improve cancer outcomes. Our cutting-edge AI models leverage genomic, clinical and imaging data to predict patient response to immunotherapy more accurately than current biomarkers. Curenetics supports physicians & lab scientists by providing personalised immunotherapy treatment plans, saving crucial time spent on ineffective treatment.



Georgie Powell
Founder Associate
georgie@curenetics.io
curenetics.io



iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery & development. Through advanced AI & photonics, we collect massive amounts of data to build a digital library of biomarkers & biological profiles, to get life-saving personalized treatments to patients faster.



Luis Valente
CEO
lvalente@ilof.tech
ilof.tech



Pangea Bio discovers and develops novel medicines to treat neurological disorders. We deploy AI to uncover promising molecules from nature, enhanced by traditional human evidence of safety and efficacy. Our lead R&D program has generated promising in vivo data across Schizophrenia, Parkinson's and Alzheimer's disease. We raised \$14m+ to date.



Dr. Alleyn Plowright
Chief Scientific Officer
alleyn@pangeabotanica.com
pangeabotanica.com



Phaim Pharma is dedicated to developing potentially preventative and curative treatments for autoimmune disease affecting 5-10% of the global population. It is both a platform and a product company, producing assets for sale or licensing in individual autoimmune diseases with a lead drug in type 1 diabetes (T1D).



Dr. Nara Daubeney
COO & Founder
nara.daubeney@phaim.co.uk
phaim.co.uk



LIFT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIFT's Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity.



Alex Blyth
Founder & CEO
ablyth@liftbiosciences.com
LIFTBioSciences.com



Plasticell is a biotechnology company that develops cell therapies through precise manipulation of stem cells using an award-winning combinatorial screening technology. Plasticell focuses on a number of therapeutic programs, including the expansion of hematopoietic stem cells and the manufacture of immune cells from iPSCs for applications in regenerative medicine and immuno-oncology.



Dr. Marina Tarunina
Research Director
marina@plasticell.co.uk
plasticell.co.uk



Sixfold Bioscience is a biotechnology company solving one of the most critical challenges preventing the greater utilization of RNA medicines: delivery. Sixfold's AI-enabled solution takes evolution as inspiration, learning and mimicking how RNA is naturally delivered to different cell types in the body.



Dr. George Foot
Co-CEO
George@sixfold.bio
sixfold.bio